Behavioral interventions in multiple sclerosis: a biopsychosocial perspective.
Standard
Behavioral interventions in multiple sclerosis: a biopsychosocial perspective. / Heesen, Christoph; Köpke, S; Kasper, Jürgen; Poettgen, Jana; Tallner, A; Mohr, D C; Gold, Stefan.
In: EXPERT REV NEUROTHER, Vol. 12, No. 9, 9, 2012, p. 1089-1100.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Behavioral interventions in multiple sclerosis: a biopsychosocial perspective.
AU - Heesen, Christoph
AU - Köpke, S
AU - Kasper, Jürgen
AU - Poettgen, Jana
AU - Tallner, A
AU - Mohr, D C
AU - Gold, Stefan
PY - 2012
Y1 - 2012
N2 - Managing uncertainty is a major challenge associated with the diagnosis of multiple sclerosis (MS). In addition to physical symptoms, neuropsychiatric symptoms are highly prevalent in this disease. Depression in particular is more common in MS than in other chronic diseases. While substantial achievements have been made in the therapy of MS and an increasing number of immunomodulatory treatments are now available, the long-term benefits of these are still a matter of debate. Importantly, while the approved therapies show good efficacy on inflammatory lesions and relapse rate, and may slow certain aspects of disease progression, improvements in function have rarely been reported. On the other hand, behavioral interventions have recently been shown to significantly improve fatigue and depression as well as motor function. In addition, recent evidence suggests that group education or face-to-face behavioral interventions may decrease inflammatory disease activity (such as relapse rate or lesion formation measured by MRI). Therefore, behavioral interventions not only ameliorate symptoms but may have the potential to modify the disease process itself.
AB - Managing uncertainty is a major challenge associated with the diagnosis of multiple sclerosis (MS). In addition to physical symptoms, neuropsychiatric symptoms are highly prevalent in this disease. Depression in particular is more common in MS than in other chronic diseases. While substantial achievements have been made in the therapy of MS and an increasing number of immunomodulatory treatments are now available, the long-term benefits of these are still a matter of debate. Importantly, while the approved therapies show good efficacy on inflammatory lesions and relapse rate, and may slow certain aspects of disease progression, improvements in function have rarely been reported. On the other hand, behavioral interventions have recently been shown to significantly improve fatigue and depression as well as motor function. In addition, recent evidence suggests that group education or face-to-face behavioral interventions may decrease inflammatory disease activity (such as relapse rate or lesion formation measured by MRI). Therefore, behavioral interventions not only ameliorate symptoms but may have the potential to modify the disease process itself.
KW - Animals
KW - Humans
KW - Exercise
KW - Combined Modality Therapy
KW - Evidence-Based Medicine
KW - Behavior, Animal
KW - Sports
KW - Cognitive Therapy/methods
KW - Social Support
KW - Neuroprotective Agents/therapeutic use
KW - Depression/etiology/prevention & control
KW - Multiple Sclerosis/drug therapy/physiopathology/psychology/therapy
KW - Animals
KW - Humans
KW - Exercise
KW - Combined Modality Therapy
KW - Evidence-Based Medicine
KW - Behavior, Animal
KW - Sports
KW - Cognitive Therapy/methods
KW - Social Support
KW - Neuroprotective Agents/therapeutic use
KW - Depression/etiology/prevention & control
KW - Multiple Sclerosis/drug therapy/physiopathology/psychology/therapy
M3 - SCORING: Journal article
VL - 12
SP - 1089
EP - 1100
JO - EXPERT REV NEUROTHER
JF - EXPERT REV NEUROTHER
SN - 1473-7175
IS - 9
M1 - 9
ER -
